|
Total Value in 2011: $16,931M* Number of Deals in 2011: 224 |
||||
|
Company (Location) |
Company (Location) |
Value (M) |
Type/Product Area |
Terms/Details (Date) |
|
|
||||
|
October |
||||
|
Acton Pharmaceuticals Inc. (Marlborough, Mass.) |
Sanofi U.S. (part of Sanofi SA; Paris) |
ND |
Licensing agreement for prescription Nasacort HFA nasal aerosol to treat nasal allergy symptoms |
Acton assumes the exclusive U.S. rights to develop and market Nasacort HFA (10/26) |
|
Arrowhead Research Corp. (Pasadena, Calif.) |
Roche Holdings AG (Basel, Switzerland) |
ND |
Arrowhead acquired RNA therapeutics assets from Roche, including a research site in Madison, Wis. |
Other Roche assets and IP acquired by Arrowhead include Roche Madison Inc., a license from Tekmira Pharmaceuticals Corp. for SNALP RNAi delivery, a liposomal nanoparticle RNAi delivery system developed by Roche, a license from Alnylam Pharmaceuticals Inc. and other licenses (10/25) |
|
Atlab Pharma SAS (Nantes, France) |
BZL Biologics LLC (New York) |
ND |
Sublicense agreement to develop (177)Lu-J591 as a prostate cancer treatment |
The agreement includes exclusive rights to manufacture, develop and commercialize the radiopharmaceutical worldwide, as well as a joint Phase IIb/III program (10/31) |
|
BeiGene Ltd. (Beijing) |
Johnson & Johnson company Janssen Pharmaceutica NV (Beerse, Belgium) |
ND |
Exclusive in-licensing and co-development agreements for two clinical-stage oncology compounds |
BeiGene will in-license intetumumab for development and commercialization in Australia, China, Hong Kong, Korea, New Zealand, Singapore and Taiwan and pay royalties to Janssen; BeiGene also is making an up-front payment to in-license MTKi-327, a kinase inhibitor, and will retain global rights for development and commercialization for human uses (10/17) |
|
DeCode Genetics Inc. (Reykjavik, Iceland) |
Pfizer Inc. (New York) |
ND |
Research collaboration to discover sequence variants associated with specific clinical phenotypes related to systemic lupus erythematosus |
DeCode and Pfizer will analyze the genomes of patients to search for sequence variants that could be useful for understanding drug targets and discovering new ones (10/13) |
|
Exonhit SA (Paris) |
Pfizer Inc. (New York) |
ND |
Research agreement to identify new Alzheimer's disease biomarkers using Exonhit's Genome-Wide SpliceArray platform |
The companies will seek to identify progression and other biomarkers that could segregate healthy elderly controls, patients with mild cognitive impairment and patients with Alzheimer's (10/11) |
|
Gilead Sciences Inc. (Foster City, Calif.) |
Boehringer Ingelheim GmbH (Ingelheim, Germany) |
ND |
Exclusive worldwide rights agreement for the research, development and commercialization of noncatalytic site integrase inhibitors for HIV |
The agreement includes the lead compound BI 224436, evaluated in a Phase Ia dose-escalation study; Boehringer will receive an undisclosed up-front payment and possible milestones and royalties (10/7) |
|
GlycoMimetics Inc. (Gaithersburg, Md.) |
Pfizer Inc. (New York) |
$340 |
Licensing agreement for rights to pan-selectin antagonist GMI-1070 for further development in the orphan indication of sickle cell crisis, as well as other indications |
GlycoMimetics could receive up to $340M in up-front and milestone payments, and is entitled to royalties on product sales (10/12) |
|
Hybrigenix SA (Paris) |
Servier (Suresnes, France) |
€42 ($57.3) |
License and research collaboration for deubiquitinating enzymes applied to oncology, neurology, psychiatry, rheumatology, ophthalmology, diabetes and cardiovascular diseases |
Hybrigenics will identify and validate new targets and screen potential agents able to modulate four undisclosed targets; it will receive an up-front payment totaling €4M ($5.5M), plus milestones of €9.5M for each successful target (10/11) |
|
Immune Design Corp. (Seattle) |
Sanofi SA (Paris) |
ND |
Early stage research collaboration to investigate the use of IDC's glucopyranosyl lipid adjuvant technology, a Toll-like receptor 4 agonist, in the allergy field |
Sanofi will evaluate the biological and immunological properties of GLA in vitro and in allergy disease models (10/27) |
|
Inovio Pharmaceuticals Inc. (Blue Bell, Pa.) |
VGX International Inc. |
ND |
Collaboration to develop SynCon vaccines for hepatitis B and C |
VGX gains marketing rights in Asia (except Japan) and Inovio gets milestones and royalties (10/11) |
|
MedImmune LLC (Gaithersburg, Md.; unit of AstraZeneca plc) |
Pfizer Inc. (New York) |
ND |
Licensing deal for CTLA-4 antibody tremelimumab for undisclosed terms |
MedImmune picks up global development rights to the drug, while Pfizer retains the rights to use tremelimumab with specified types of combination therapies (10/4) |
|
Miragen Therapeutics Inc. (Boulder, Colo.) |
Les Laboratoires Servier (France) |
$352 |
Licensing agreement for two lead compounds in Miragen's preclinical micro-RNA program for cardiovascular disease |
They will jointly develop a third in a deal valued at up to $352M; Miragen could receive up to $45M over the next three years in up-front fees, research support and near-term milestones; the remaining money is tied to regulatory and commercial milestones, and the deal includes double-digit royalties in all markets except the U.S. and Japan (10/19) |
|
Ono Pharmaceutical Co. Ltd. (Osaka, Japan) |
Merck KGaA (Darmstadt, Germany) |
$19.5 |
Deal giving Merck worldwide, exclusive rights to develop and commercialize ONO-4641 for multiple sclerosis, outside Japan, Korea and Taiwan; and a deal providing Ono with co-development and co-marketing rights for Stimuvax |
Merck will pay $19.5M up front, plus undisclosed milestones under the first deal; the second deal includes a $6.6M up front payment for Merck (10/5) |
|
Progenra Inc. (Malvern, Pa.) |
Ono Pharmaceutical Co. Ltd. (Osaka, Japan) |
ND |
Collaboration to develop high-throughput screening assays using Progenra's technology for multiple targets in the ubiquitin pathway |
Terms were not disclosed (10/12) |
|
Puma Biotechnology Inc. (Los Angeles) |
Pfizer Inc. (New York) |
ND |
Deal giving Puma rights to neratinib, a panHER inhibitor |
Puma has full responsibility for global development and commercialization in exchange for milestone payments and royalties (10/7) |
|
SemBioSys Genetics Inc. (Calgary) |
Tasly Pharmaceuticals Ltd. (Tianjin, China) |
ND |
Agreement for development and commercialization of pharmaceutical, functional food and nutraceutical products |
SemBioSys will have 30% ownership and profit sharing in the joint venture, plus licensing rights to research and develop new products (10/12) |
|
Syntaxin Ltd. (Oxford, UK) |
Ipsen SA (Paris) |
$99 |
Research collaboration focused on botulinum toxin |
Deal gives Syntaxin $9M over three years for discovery work, with additional fees for any compounds that go into development, and a potential $90M in commercial milestones; Ipsen will have exclusive commercialization rights (10/21) |
|
X-Body Inc. (Waltham, Mass.) |
Tanabe Research Laboratories U.S.A. Inc. (subsidiary of Mitsubishi Tanabe Pharma Corp.; Osaka, Japan) |
ND |
Partnership for X-Body to screen antibody libraries against target cells of therapeutic interest to TRL to identify tissue-specific epitopes and human antibody therapeutic candidates in autoimmune disease |
TRL will fund the collaboration and has the option to negotiate rights to the antibodies discovered for further research, development and commercialization (10/5) |
|
Zosano Pharma Inc. (Fremont, Calif.) |
Asahi Kasei Pharma Corp. (Tokyo) |
$32.5 |
Long-term collaboration to develop, commercialize and supply a weekly transdermal patch formulation of Teribone for osteoporosis for a high risk of failure |
AKP will get exclusive rights to the patch formulation, using Zosano's microprojection technology in Japan, Korea, China and Taiwan in exchange for $7.5M up front, and more than $25M in milestone payments, plus royalties and reimbursement for development and manufacturing costs (10/11) |
|
November |
||||
|
Alnylam Pharmaceuticals Inc. (Cambridge, Mass.) |
GlaxoSmithKline plc (London) |
ND |
Collaboration focused on the use of Alnylam's VaxiRNA technology to produce certain GSK vaccine products |
GSK will provide research funding in addition to potential milestones and payments on unit product sales (11/2) |
|
ArQule Inc. (Woburn, Mass.) |
Daiichi Sankyo Co. Ltd. (Tokyo) |
ND |
Licensing agreement for AKT inhibitor ARQ 092 |
Daiichi gets exclusive rights to the compound on a worldwide basis (11/11) |
|
Aslan Pharmaceuticals Pte Ltd. (Singapore) |
Bristol-Myers Squibb Co. (New York) |
ND |
Partnership to accelerate the development of BMS-777607, a small-molecule inhibitor of the MET receptor tyrosine kinase for the treatment of solid tumors |
Aslan will receive exclusive rights to develop and commercialize the BMS drug in Australia, China, Korea, Taiwan and other selected Asian countries while BMS retains exclusive rights in the rest of the world (11/4) |
|
CureVac GmbH (Tubingen, Germany) |
Sanofi Pasteur (Paris), Sanofi Pasteur VaxDesign Corp. (Orlando, Fla.), In-CellArt SAS (Nantes, France) and the Defense Advanced Research Projects Agency |
$33.1 |
CureVac entered a five-way, $33.1M research collaboration to develop mRNA-based vaccines against undisclosed infectious disease pathogens, using its RNActive technology |
CureVac also entered an option agreement with Sanofi Pateur for Sanofi to pay up to $137.3M in up-front and milestone payments linked to the successful development of a prophylactic or a therapeutic vaccine; the money could be more if the vaccine is both prophylactic and therapeutic (11/16) |
|
Gilead Sciences Inc. (Foster City, Calif.) |
Tibotec Pharmaceuticals (unit of Johnson & Johnson; New Brunswick, N.J.) |
ND |
Deal to develop and commercialize a single-tablet HIV regimen combining Prezista with Gilead's Emtriva |
Gilead is responsible for formulation, manufacturing, registration and distribution and commercialization; Tibotec has the right to co-detail the single-tablet regimen in certain major markets (11/17) |
|
Hawaii Biotech Inc. (Honolulu) |
Merck & Co. Inc. (Whitehouse Station, N.J.) |
ND |
Exclusive license deal to tick-borne encephalitis and malaria virus vaccine technology |
The deal also includes a nonexclusive license to recombinant protein expression technology from Merck (11/2) |
|
pSivida Corp. (Watertown, Mass.) |
Global pharmaceutical company |
ND |
Agreement to evaluate pSivida's Durasert technology in the area of ophthalmology |
Financial terms were not disclosed (11/23) |
|
Signum Biosciences Inc. (Princeton, N.J.) |
GlaxoSmithKline plc (London) |
ND |
Agreement to advance Signum's phosphatase screening technology, which targets the PP2A as a key mechanism in Alzheimer's disease |
Signum gains research support and potential downstream milestone payments; GSK receives the exclusive right to use Signum's phosphatase screening technology for internal neuroscience research and development (11/11) |
|
|
||||
|
Notes: The date indicated refers to the BioWorld Today issue in which the news item can be found. * The total value represents the amount of disclosed money involving collaborations between biotechnology and pharmaceutical companies, including manufacturing, marketing and distribution agreements detailed in the following chart. ** Denotes the date the item ran in BioWorld International. |
||||